Production (Stage)
Innate Pharma S.A.
IPHA
$2.08
-$0.09-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -552.82% | -25.62% | 42.01% | 63.06% | 85.98% |
| Total Depreciation and Amortization | -60.81% | -58.22% | -55.90% | -23.44% | 18.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.35% | -95.93% | -99.12% | -97.23% | -95.47% |
| Change in Net Operating Assets | 222.05% | 200.62% | 165.23% | 40.40% | -156.00% |
| Cash from Operations | 78.79% | 60.52% | 40.86% | -4.80% | -82.12% |
| Capital Expenditure | -11.47% | 6.67% | 22.02% | 27.43% | 34.14% |
| Sale of Property, Plant, and Equipment | -- | -1.10% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -53.96% | 35.80% | 855.54% | 838.57% | 820.61% |
| Cash from Investing | -55.41% | 36.99% | 1,057.37% | 1,070.10% | 1,092.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -278.48% | -181.17% | -94.85% | -61.01% | -16.54% |
| Issuance of Common Stock | 641.27% | 309.61% | -60.45% | -3.08% | 99.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -205.67% | -174.55% | -145.04% | -84.77% | -10.09% |
| Foreign Exchange rate Adjustments | -284.37% | -198.35% | -134.36% | 335.82% | 160.80% |
| Miscellaneous Cash Flow Adjustments | -110.00% | -86.67% | -75.00% | -71.43% | -66.67% |
| Net Change in Cash | 69.04% | 87.10% | 95.31% | 68.89% | 25.98% |